Vertex has signed a definitive agreement to acquire Alpine Immune Sciences for $65 per unit making it a total of ~$4.9B in cash. The transaction will conclude in the Q2’24
The acquisition will add Alpine’s povetacicept (ALPN-303) to the company’s portfolio, which demonstrated effectiveness in the P-II study of IgA nephropathy. The drug’s P-III clinical evaluation in anticipated in H2’24
Povetacicept is a dual BAFF (B cell activating factor) & APRIL (a proliferation inducing ligand) cytokines antagonist which are responsible for the pathogenesis of various autoimmune diseases by activating, differentiating & sustaining B cells, T cells & innate immune cells
Ref: Vertex | Image: Vertex
Related News:- Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
